Stock Market News
Earnings suffer in year of change for Immunodiagnostic Systems
Immunodiagnostic Systems reported a 5% fall in revenue for the year to 31 March in its final results on Wednesday, to £37.9m.
The AIM-traded firm did see a 7% improvement in its automated business revenue to £22.9m, though that was more than offset by declines in manual business revenue, which was off 3% to £12.4m, and in revenue from its licensing and technology business, which plunged 54% to £2.7m.
Adjusted EBITDA was down 22% at £6m, with adjusted earnings per share plummeting 61% to 5.7p.
Immunodiagnostic said its free cash outflow was £1.4m, swinging from an inflow of £4.8m last year, while its closing cash was 10% below where it was at the end of the prior year, at £28.5m.
"Group revenues declined 5% year on year, though they showed a decline of 8% on a like for like basis," said CEO Jaap Stuut.
"This decline was mainly driven by the expected reduction in antibody royalty income."
Stuut said its core laboratory business, comprising its automated and manual business units, generated consistent revenues with the prior year on a like-for-like basis.
"I believe we have made good progress in both the restructuring of the commercial operations of the group, as well as adding new assay fields during the year, and whilst there is more work to be done, I look forward to returning the group to modest revenue growth in the next financial year."
The AIM-traded firm did see a 7% improvement in its automated business revenue to £22.9m, though that was more than offset by declines in manual business revenue, which was off 3% to £12.4m, and in revenue from its licensing and technology business, which plunged 54% to £2.7m.
Adjusted EBITDA was down 22% at £6m, with adjusted earnings per share plummeting 61% to 5.7p.
Immunodiagnostic said its free cash outflow was £1.4m, swinging from an inflow of £4.8m last year, while its closing cash was 10% below where it was at the end of the prior year, at £28.5m.
"Group revenues declined 5% year on year, though they showed a decline of 8% on a like for like basis," said CEO Jaap Stuut.
"This decline was mainly driven by the expected reduction in antibody royalty income."
Stuut said its core laboratory business, comprising its automated and manual business units, generated consistent revenues with the prior year on a like-for-like basis.
"I believe we have made good progress in both the restructuring of the commercial operations of the group, as well as adding new assay fields during the year, and whilst there is more work to be done, I look forward to returning the group to modest revenue growth in the next financial year."
Related share prices |
---|
Immunodiagnostic Systems Holdings (IDH) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price